C erebral cavernous malformations (CCMs) are common vascular malformations that arise primarily in the central nervous system. 1 CCMs are typically diagnosed in middle age and constitute an important cause of stroke and neurological deficit in younger individuals. One third of CCMs are familiar, and positional cloning studies have identified loss of function mutations in 3 genes, KRIT1, CCM2 and PDCD10, as causal for this disease. 1 
KRIT1, CCM2
, and PDCD10 encode intracellular adaptor proteins that have been shown to form a single biochemical complex that is bound by the transmembrane receptor Heart of Glass (HEG), 2 but the role of HEG in CCM disease has not been defined.
Fish and mouse genetic studies have demonstrated that HEG, KRIT1, CCM2, and PDCD10 function together in endothelial cells during formation of the heart and vasculature.
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gene inactivation, pups were given 100 μg tamoxifen via intragastric injection at P1 followed by oral administration of 50 μg at P3 and P5.
Human Studies
Twenty-one unrelated patients and 6 healthy controls were used. The study was approved by the local ethics committee.
Sequencing and Quantitative Multiplex Polymerase Chain Reaction of Short Fluorescent Fragment Analysis
HEG1 sequencing was performed after coding exon amplification using primers indicated in Table I in the online-only Data Supplement. HEG genomic rearrangements were assessed using the Quantitative Multiplex Polymerase Chain Reaction of Short Fluorescent fragments method as described.
Results
We have previously found that Heg Table II in the online-only Data Supplement). Thus, the loss of HEG, in contrast to loss of CCM2, does not result in CCM formation in mice.
To address the role of HEG in CCM formation further, we conditionally deleted 1 Ccm2 allele in Tie2-CreERT2;Heg 
;Ccm2
−/− animals (mean lesion number of 17 and 16, respectively; n=3 for both groups; Figure 3D ).
To determine whether HEG1 might be a human CCM disease gene, we analyzed this gene in 21 unrelated patients with CCMs identified by cerebral MRI and pathological examination, and in whom no point mutation or copy number anomaly was detected in KRIT1, CCM2, or PDCD10. Eighteen cases were sporadic with multiple lesions and 3 were familial (≥1 relative with CCM lesions; Table III in the online-only Data Supplement). None of these patients with CCM exhibited germline mutations or large deletions in HEG1. Sixteen exonic polymorphisms were detected. All were present in single-nucleotide polymorphism databases (Table IV in 
Discussion
How loss of CCM signaling causes CCM formation and why CCMs form so specifically in the central nervous system remain unanswered questions. Our studies reveal roles for HEG during embryonic CCM signaling but not in the postnatal pathway that underlies CCM pathogenesis. One interpretation of these studies is that there exist multiple upstream inputs to the CCM signaling pathway in endothelial cells (eg, HEG during cardiovascular growth and another to prevent CCM formation and perhaps maintain vascular barrier function elsewhere). Definitive proof of distinct upstream activators of CCM signaling will require the molecular identification of such proteins and genetic studies linking their function to CCM formation. Alternatively, it remains possible that HEG couples to CCM signaling in the central nervous system endothelium but that its loss does not disable the pathway to the extent required for lesion formation. The lack of CCMs in postnatal Tie2-CreERT2;Heg −/− ;Ccm2 fl/+ animals that carry an endothelial deficiency state equivalent to that which causes embryonic phenotypes identical to those conferred by complete KRIT1 or CCM2 deficiency suggests that these studies have a reasonable sensitivity to detect a role for HEG in CCM formation. In either case, our studies indicate that HEG cannot be the sole upstream activator of CCM signaling in the central nervous system endothelium; thus the remarkable specificity of this disease for that organ is likely to reflect the function of other activator(s) that remain to be identified.
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